Ipsen has announced positive results from its phase IIa clinical trial assessing Dysport® in the treatment of neurogenic detrusor overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.
Ipsen has announced positive results from its phase IIa clinical trial assessing Dysport® in the treatment of neurogenic detrusor overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.
Results show that treatment with Dysport − an injectable form of botulinum toxin type A (BTX-A) − was associated with a mean reduction from baseline of urinary incontinence episodes greater than 75% a period of 12 weeks after the injection, regardless of how the drug is administered.
These results were achieved with a single dose of Dysport 750 Units injected in either 15 or 30 sites in the detrusor muscle. Efficacy was confirmed by improvement in urodynamic parameters and quality of life.
"These results are very encouraging for the Dysport franchise, which has the opportunity of potentially expanding into urology, a core therapeutic area for Ipsen" said Claude Bertrand, executive vice-president R&D and chief scientific officer at the French pharmaceutical company.
"We are excited about the potential benefits Dysport could bring to patients suffering from NDO," he added.